Quality Over Quantity Authors: Amedeo Tirandi, Luca Liberale, Giovanni G Camici Published: 2026 ABSTRACT Corresponding AuthorKey words: antioxidant, atorvastatin, lipoprotein(a) Does impact derive from quantity or quality? This dichotomy lies at the heart of lipoprotein(a) [Lp(a)] biology, where both circulating levels and the oxidative and inflammatory properties of the particle itself contribute to determining its atherogenic potential. Lp(a) is a lipoprotein structurally related to low-density lipoprotein (LDL), composed of a lipid-rich core containing cholesteryl esters, triglycerides, and phospholipids, with apolipoprotein B-100 (ApoB-100) as its principal structural protein. It is uniquely characterized by the covalent attachment of apolipoprotein(a) [apo(a)] to ApoB-100 via a single disulfide bond. Apo(a) shares close structural homology with plasminogen, conferred by the presence of kringle domains, which grant Lp(a) possible proatherogenic and prothrombotic properties.1 Circulating Lp(a) levels are largely genetically determined—up to approximately 90%—and are minimally influenced by diet, lifestyle, or conventional lipid-lowering therapies.1 As a result, Lp(a) quantification is recommended once in a lifetime and used for cardiovascular risk stratification. Elevated Lp(a) levels are causally associated with atherosclerotic cardiovascular disease, including coronary artery disease, stroke, peripheral artery disease, and aortic valve stenosis.2 Importantly, Lp(a) contributes to the so-called residual cardiovascular risk, persisting even in patients with well-controlled LDL cholesterol. Mechanistically, Lp(a) integrates several pathogenic pathways. In addition to its LDL-like atherogenicity, Lp(a) is the predominant carrier of oxidized phospholipids (oxPL) in human plasma, a property attributable to high-affinity oxPL binding sites within the apo(a) kringle domains.3 These bioactive lipid species promote endothelial activation, monocyte recruitment, vascular inflammation, and cytokine release, and further amplify oxidative stress within atherosclerotic plaques. Moreover, apo(a), through its plasminogen-like structure, competes with plasminogen for binding to lysine residues on fibrin and cell surfaces; unlike plasminogen, however, apo(a) cannot be cleaved into an active protease, potentially impairing fibrinolysis and promoting a prothrombotic state. Despite its clear pathogenic role, therapeutic strategies targeting Lp(a) remain limited. Statins, the cornerstone of lipid-lowering therapy, do not affect Lp(a) concentrations; their cardiovascular benefit is therefore primarily attributed to LDL-C lowering and concomitant pleiotropic effects. In contrast, proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors, such as evolocumab and alirocumab, were shown to reduce Lp(a) levels by approximately 25%-30% in phase 2 studies, with more modest effects observed in large-scale outcomes trials—a reduction of approximately 27% with evolocumab in the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial4 and 23% with alirocumab in the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab)5—although the underlying mechanisms remain incompletely understood. Lipoprotein apheresis can achieve acute reductions of Lp(a), but its invasive nature, cost, and need for repeated sessions limit widespread applicability. More recently, RNA-based therapies have emerged as the most promising targeted approaches. Antisense oligonucleotides, such as pelacarsen (also known as AKCEA-APO(a)-LRx and TQJ230), directly inhibit hepatic apo(a) synthesis by targeting LPA messenger RNA, achieving dose-dependent reductions in Lp(a) of up to approximately 80% in phase 2 studies.6 Similarly, small interfering RNA therapies—including olpasiran, zerlasiran, and lepodisiran—operate through a mechanistically related but distinct RNA interference pathway and have demonstrated even more profound reductions: phase 2 data from the OCEAN(a)-DOSE (Olpasiran Trials of Cardiovascular Events and Lipoprotein[a] Reduction–Dose Finding Study) trial showed Lp(a) reductions exceeding 95% with olpasiran at higher doses,7 while lepodisiran achieved reductions in Lp(a) of up to approximately 95% in the phase 2 ALPACA trial.8 More recently, muvalaplin has emerged as the first oral agent targeting Lp(a), functioning through a distinct mechanism by inhibiting the intracellular assembly of the Lp(a) particle rather than suppressing apo(a) mRNA; phase 2 data from the KRAKEN trial demonstrated meaningful reductions in Lp(a) with an acceptable safety profile.9 All of these agents represent a major therapeutic advance; however, long-term cardiovascular outcome data are still awaited from ongoing phase 3 trials (Lp(a)HORIZON for pelacarsen, OCEAN(a) for olpasiran, and ACCLAIM-Lp(a) for lepodisiran), and challenges related to cost, accessibility, and scalability remain to be resolved. Collectively, current strategies have largely focused on reducing circulating concentrations of Lp(a). However, they do not address an equally important aspect: the biological behavior of Lp(a), particularly the oxidative modification of its associated phospholipids and the resulting pro-inflammatory oxPL burden it carries.3 The distinction between quantity and quality is likely critical in determining its atherogenic potential. Addressing this qualitative dimension, while awaiting the results of ongoing outcome trials and given the anticipated challenges in terms of cost and scalability of novel RNA-based agents, drug repositioning offers an attractive and immediately applicable strategy. Statins represent a particularly interesting candidate in this regard. Beyond LDL-C reduction, statins exhibit pleiotropic properties, including anti-inflammatory, endothelial, and antioxidant effects. Although they do not lower Lp(a) levels, they consistently reduce cardiovascular events even in individuals with elevated Lp(a), raising the possibility that they may influence the qualitative properties of lipoproteins. Against this background, the study by Sherratt et al10 provides important mechanistic insight into this hypothesis. The authors investigated the effects of atorvastatin metabolites—specifically ortho- and para-hydroxylated derivatives—on the oxidation of plasma lipoproteins enriched with varying proportions of Lp(a), as well as on cholesterol-rich model membranes. They observed that Lp(a) is more susceptible to oxidative modification than other ApoB-containing particles, with a nonlinear increase at higher enrichment levels. Notably, both atorvastatin metabolites inhibited oxidation in a time- and dose-dependent manner, in contrast to other statins. These findings suggest that the antioxidant effects are not a class effect of statins but rather depend on specific structural features. The investigators propose that the phenolic moiety present in hydroxylated atorvastatin metabolites facilitates partitioning into the lipoprotein lipid phase, positioning the molecule favorably to intercept lipid peroxidation chain reactions. In this lipid-phase environment, free radical scavenging occurs predominantly through hydrogen atom transfer, whereby the phenolic hydroxyl group donates a hydrogen atom to a peroxyl radical, quenching the chain reaction (Figure 1). The resulting phenoxy radical is stabilized by resonance delocalization of the unpaired electron into the aromatic ring, generating a low-reactivity species that does not efficiently abstract hydrogen atoms from lipid substrates and thereby limits the propagation of oxidative reactions. This mechanistic explanation provides a plausible link between the chemical structure of hydroxylated atorvastatin metabolites and their antioxidant activity. Proposed Mechanism for the Inhibition of lipoprotein(a) Oxidation by Hydroxylated Atorvastatin Metabolites In a copper sulfate-induced oxidation model, lipid peroxyl radicals (ROO•) propagate the oxidative chain reaction within the lipoprotein(a) particle. The phenolic moiety of hydroxylated atorvastatin metabolites (Ar–OH) scavenges ROO• through hydrogen atom transfer (HAT), donating a hydrogen atom to yield a stable, nonradical lipid hydroperoxide (ROOH) and a phenoxy radical (Ar–O•). The unpaired electron of Ar–O• delocalizes across the oxygen and the ortho and para ring carbons—as indicated by the resonance arrows—generating a low-reactivity species that terminates the oxidative chain. This study has several notable strengths. It combines mechanistic depth with comparative approaches, evaluating multiple statins and isolating the specific contribution of atorvastatin metabolites. The use of both lipoprotein fractions and membrane models strengthens the biological plausibility of the findings. Nevertheless, certain limitations should be acknowledged. The study is based on in vitro models, which may not fully recapitulate in vivo conditions. Oxidation was induced using copper sulfate, a widely used but artificial system that may not reflect physiological oxidative processes. Additionally, as in many in vitro studies, the concentrations of metabolites employed may differ from those achievable in humans. As such, the clinical relevance of these findings requires further validation in experimental models and, ultimately, in human studies. Future research should aim to confirm these observations in vivo and to explore whether modulation of Lp(a) oxidation translates into measurable cardiovascular benefit. The identification of biomarkers reflecting oxidative modification of Lp(a) could facilitate this process. Moreover, these findings raise the possibility that combining Lp(a)-lowering therapies with agents targeting oxidative pathways may provide synergistic effects. In conclusion, this study shifts the focus from the quantity to the quality of Lp(a), highlighting oxidation as a key determinant of its pathogenicity. While emerging therapies aim to reduce circulating levels, targeting the biological behavior of Lp(a) may represent a complementary and potentially impactful strategy. Importantly, this work underscores the value of revisiting established drugs to uncover previously unrecognized mechanisms, paving the way toward more nuanced and cost-effective approaches in cardiovascular prevention. Funding Support and Author Disclosures Dr Tirandi has received research funding from the Theodor and Ida Herzog-Egli Foundation for a separate project unrelated to the present work. Dr Liberale and Dr Camici report a coinventorship on issued patent WO2020226993 (IL-1α inhibition in stroke, held by the University of Zurich) and royalty income through the University of Zurich from licensing of WO2020226993 to XBiotech Inc. Dr Camici is an educational consultant to the Zurich Heart House Foundation. Dr Camici received financial support from the Swiss Heart Foundation outside this work. Dr Liberale has received financial support from the Italian Ministry of Health and ERA4Health outside this work. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References